Skip to main content
. 2020 Jul 24;9(5):583–595. doi: 10.1159/000508724

Table 3.

Cause of treatment discontinuation (incidence rate >2%)

Eligible patients (n = 1,775), n (%)
HAIC (n = 429) sorafenib (n = 1,346)
Any adverse event 111 (25.9) 399 (29.6)
Catheter-related adverse events 27 (6.7) 0
Liver failure 20 (4.7) 77 (5.7)
General disorders 3 (0.7) 49 (3.6)
Rash 0 30 (2.2)
Catheter occlusion 10 (2.3) 0
Hand-foot-skin syndrome 0 30 (2.2)
Anorexia 1 (0.2) 28 (2.1)
Renal failure 9 (2.1) 9 (0.7)
Abdominal pain 9 (2.1) 2 (0.1)